Experimental Hematology
Volume 37, Issue 9 , Pages 1016-1021 , September 2009

JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera

  • Alessandra Carobbio

      Affiliations

    • Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • ,
  • Guido Finazzi

      Affiliations

    • Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • ,
  • Elisabetta Antonioli

      Affiliations

    • Hematology Department, Università degli Studi di Firenze, Florence, Italy
    • ,
  • Paola Guglielmelli

      Affiliations

    • Hematology Department, Università degli Studi di Firenze, Florence, Italy
    • ,
  • Alessandro M. Vannucchi

      Affiliations

    • Hematology Department, Università degli Studi di Firenze, Florence, Italy
    • ,
  • Chiara M. Dellacasa

      Affiliations

    • Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • ,
  • Silvia Salmoiraghi

      Affiliations

    • Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • ,
  • Federica Delaini

      Affiliations

    • Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • ,
  • Alessandro Rambaldi

      Affiliations

    • Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • ,
  • Tiziano Barbui

      Affiliations

    • Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    • Corresponding Author InformationOffprint requests to: Tiziano Barbui, M.D., Ospedali Riuniti di Bergamo, Largo Barozzi 1 24128 Bergamo, Italy

Received 20 April 2009 ,Revised 16 June 2009 ,Accepted 17 June 2009.

References 

  1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061
  2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790
  3. Kittur J, Knudson RA, Lasho TL, et al. Clinical Correlates of JAK2 V617F Allele Burden in Essential Thrombocythemia. Cancer. 2007;109:2279–2284
  4. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–1953
  5. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008;111:2785–2789
  6. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009 Apr 16. [Epub ahead of print].
  7. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299–1307
  8. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112:3135–3137
  9. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26:2732–2736
  10. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology. 2008;13:71–76
  11. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Vougarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33:67–73
  12. Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica. 2008;93:1412–1414
  13. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009 Mar 17. [Epub ahead of print].
  14. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135–136
  15. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840–846
  16. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21:1952–1959
  17. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:4030–4036
  18. Gale RE, Allen AJ, Nash MJ, Linch DC. Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood. 2007;109:1241–1243
  19. Tefferi A, Strand JJ, Lasho TL, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia. 2007;21:2074–2075
  20. Theocharides A, Passweg JR, Medinger M, et al. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008;93:1890–1893
  21. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2008;109:2310–2313

PII: S0301-472X(09)00219-7

doi: 10.1016/j.exphem.2009.06.006

Experimental Hematology
Volume 37, Issue 9 , Pages 1016-1021 , September 2009

Article Tools

* Image Usage & Resolution